PL368565A1 - Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma - Google Patents

Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Info

Publication number
PL368565A1
PL368565A1 PL02368565A PL36856502A PL368565A1 PL 368565 A1 PL368565 A1 PL 368565A1 PL 02368565 A PL02368565 A PL 02368565A PL 36856502 A PL36856502 A PL 36856502A PL 368565 A1 PL368565 A1 PL 368565A1
Authority
PL
Poland
Prior art keywords
lasik
trauma
injury
compounds
treating conditions
Prior art date
Application number
PL02368565A
Other languages
English (en)
Polish (pl)
Inventor
Mark R. Hellberg
Lok-Hou Pang
John M. Yanni
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of PL368565A1 publication Critical patent/PL368565A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL02368565A 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma PL368565A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
PL368565A1 true PL368565A1 (en) 2005-04-04

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368565A PL368565A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Country Status (10)

Country Link
EP (1) EP1420791A4 (xx)
JP (1) JP2005502678A (xx)
CN (1) CN1549718A (xx)
AR (1) AR036194A1 (xx)
BR (1) BR0212151A (xx)
CA (1) CA2455896A1 (xx)
MX (1) MXPA04001255A (xx)
PL (1) PL368565A1 (xx)
WO (1) WO2003020281A1 (xx)
ZA (1) ZA200400837B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1616577T3 (pl) * 2003-04-18 2012-02-29 Senju Pharma Co 2-chloro-6,7-dimetoksy-N-5 [5-(1)H-indazolilo]chinazolino-4-amina, dichlorowodorek N-(1-benzylo-4-piperydynylo)- 1H-indazolo-5-aminy, kwas 4-[2-(2,3,4,5,6-pentafluorofenylo)akryloilo] cynamonowy i chlorowodorek fasudilu do zastosowania w naprawianiu percepcji rogówki
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
JPWO2005102375A1 (ja) * 2004-04-23 2008-03-06 千寿製薬株式会社 Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤
CN1795196B (zh) 2004-06-03 2013-07-24 千寿制药株式会社 酰胺化合物在制备用于修复角膜敏感性的药剂中的应用
EP1859795A4 (en) 2005-03-15 2008-06-04 Ono Pharmaceutical Co THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
AU2001261360A1 (en) * 2000-05-10 2001-11-20 Alcon, Inc. R-eliprodil for treating glaucoma

Also Published As

Publication number Publication date
JP2005502678A (ja) 2005-01-27
EP1420791A4 (en) 2004-09-15
MXPA04001255A (es) 2004-05-27
WO2003020281A1 (en) 2003-03-13
CN1549718A (zh) 2004-11-24
EP1420791A1 (en) 2004-05-26
AR036194A1 (es) 2004-08-18
BR0212151A (pt) 2004-08-24
ZA200400837B (en) 2005-02-02
CA2455896A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
EP1592435A4 (en) EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
DE60045048D1 (de) Skleraprothese zur Behandlung der Weitsichtigkeit und anderer Augenkrankheiten
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
WO2000018387A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
HU0002963D0 (en) Methods and compositions for treating diseases and conditions of the eye field of invention
WO2000066139A3 (en) Biochemical methods that eliminate corneal scars, opacification and haze
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
EP1420791A4 (en) USE OF COMPOUNDS FOR THE TREATMENT OF CONDITIONS CONSECUTIVE TO CORNEAL NERVE INJURY AFTER LASIK OR OTHER TRAUMA OR SURGERY OF THE EYE
EP1406648A4 (en) USE OF ANGIOTENSIN I DERIVATIVE AGENT FOR THE TREATMENT AND PREVENTION OF INFECTIOUS HEART DAMAGE AND DISEASES
EP1581209A4 (en) NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2005102297A3 (en) Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma
AU2002361516A1 (en) Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
AU4114301A (en) Treatment of ocular hypertension and glaucoma
MXPA04002098A (es) El uso de estrogenos no afeminantes como agentes retinoprotectores para el tratamiento del glaucoma.
IL163938A0 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
TWI345980B (en) Pharmaceutical compositions for preventing or treating injuries of brain tissue